Literature DB >> 26747502

Combination of angiotensin II and l-NG-nitroarginine methyl ester exacerbates mitochondrial dysfunction and oxidative stress to cause heart failure.

Dale J Hamilton1, Aijun Zhang2, Shumin Li2, Tram N Cao2, Jessie A Smith2, Indira Vedula2, Andrea M Cordero-Reyes3, Keith A Youker3, Guillermo Torre-Amione4, Anisha A Gupte5.   

Abstract

Mitochondrial dysfunction has been implicated as a cause of energy deprivation in heart failure (HF). Herein, we tested individual and combined effects of two pathogenic factors of nonischemic HF, inhibition of nitric oxide synthesis [with l-N(G)-nitroarginine methyl ester (l-NAME)] and hypertension [with angiotensin II (AngII)], on myocardial mitochondrial function, oxidative stress, and metabolic gene expression. l-NAME and AngII were administered individually and in combination to mice for 5 wk. Although all treatments increased blood pressure and reduced cardiac contractile function, the l-NAME + AngII group was associated with the most severe HF, as characterized by edema, hypertrophy, oxidative stress, increased expression of Nppa and Nppb, and decreased expression of Atp2a2 and Camk2b. l-NAME + AngII-treated mice exhibited robust deterioration of cardiac mitochondrial function, as observed by reduced respiratory control ratios in subsarcolemmal mitochondria and reduced state 3 levels in interfibrillar mitochondria for complex I but not for complex II substrates. Cardiac myofibrils showed reduced ADP-supported and oligomycin-inhibited oxygen consumption. Mitochondrial functional impairment was accompanied by reduced mitochondrial DNA content and activities of pyruvate dehydrogenase and complex I but increased H2O2 production and tissue protein carbonyls in hearts from AngII and l-NAME + AngII groups. Microarray analyses revealed the majority of the gene changes attributed to the l-NAME + AngII group. Pathway analyses indicated significant changes in metabolic pathways, such as oxidative phosphorylation, mitochondrial function, cardiac hypertrophy, and fatty acid metabolism in l-NAME + AngII hearts. We conclude that l-NAME + AngII is associated with impaired mitochondrial respiratory function and increased oxidative stress compared with either l-NAME or AngII alone, resulting in nonischemic HF.
Copyright © 2016 the American Physiological Society.

Entities:  

Keywords:  angiotensin II; heart failure; mitochondria; nitric oxide; oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 26747502     DOI: 10.1152/ajpheart.00746.2015

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  11 in total

Review 1.  Nitric oxide: what's new to NO?

Authors:  Kedar Ghimire; Helene M Altmann; Adam C Straub; Jeffrey S Isenberg
Journal:  Am J Physiol Cell Physiol       Date:  2016-12-14       Impact factor: 4.249

2.  Knocking down Cabin1 induces glomerular podocyte injury.

Authors:  Yueqiang Wen; Lingling Liu; Qingdong Xu; Peilan Zhou; Huiyuan Li; Zebin Wang; Jianbo Liang
Journal:  Int Urol Nephrol       Date:  2018-01-24       Impact factor: 2.370

3.  Tead1 is essential for mitochondrial function in cardiomyocytes.

Authors:  Ruya Liu; Rajaganapathi Jagannathan; Lingfei Sun; Feng Li; Ping Yang; Jeongkyung Lee; Vinny Negi; Eliana M Perez-Garcia; Sruti Shiva; Vijay K Yechoor; Mousumi Moulik
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-06-05       Impact factor: 4.733

4.  Improved Cardiovascular Function in Old Mice After N-Acetyl Cysteine and Glycine Supplemented Diet: Inflammation and Mitochondrial Factors.

Authors:  Katarzyna A Cieslik; Rajagopal V Sekhar; Alejandro Granillo; Anilkumar Reddy; Guillermo Medrano; Celia Pena Heredia; Mark L Entman; Dale J Hamilton; Shumin Li; Erin Reineke; Anisha A Gupte; Aijun Zhang; George E Taffet
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-08-10       Impact factor: 6.053

Review 5.  Melatonin, mitochondria and hypertension.

Authors:  Ovidiu C Baltatu; Fernanda G Amaral; Luciana A Campos; Jose Cipolla-Neto
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

6.  Negligible effect of eNOS palmitoylation on fatty acid regulation of contraction in ventricular myocytes from healthy and hypertensive rats.

Authors:  Chun Li Jin; Yu Na Wu; Ji Hyun Jang; Zai Hao Zhao; Goo Taeg Oh; Sung Joon Kim; Yin Hua Zhang
Journal:  Pflugers Arch       Date:  2017-04-25       Impact factor: 3.657

7.  A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome.

Authors:  Akram Khan; Cody Benthin; Brian Zeno; Timothy E Albertson; John Boyd; Jason D Christie; Richard Hall; Germain Poirier; Juan J Ronco; Mark Tidswell; Kelly Hardes; William M Powley; Tracey J Wright; Sarah K Siederer; David A Fairman; David A Lipson; Andrew I Bayliffe; Aili L Lazaar
Journal:  Crit Care       Date:  2017-09-07       Impact factor: 9.097

8.  Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model.

Authors:  Joseph C McCarthy; Mark Aronovitz; Jennifer J DuPont; Timothy D Calamaras; Iris Z Jaffe; Robert M Blanton
Journal:  JACC Basic Transl Sci       Date:  2017-06-26

9.  Role of Endothelial and Mesenchymal Cell Transitions in Heart Failure and Recovery Thereafter.

Authors:  Guangyu Wang; Ana Sofia Cruz; Keith Youker; Hernan G Marcos-Abdala; Rajarajan A Thandavarayan; John P Cooke; Guillermo Torre-Amione; Kaifu Chen; Arvind Bhimaraj
Journal:  Front Genet       Date:  2021-01-15       Impact factor: 4.599

10.  BYD Ameliorates Oxidative Stress-Induced Myocardial Apoptosis in Heart Failure Post-Acute Myocardial Infarction via the P38 MAPK-CRYAB Signaling Pathway.

Authors:  Yi Zhang; Chun Li; Hui Meng; Dongqing Guo; Qian Zhang; Wenji Lu; Qixin Wang; Yong Wang; Pengfei Tu
Journal:  Front Physiol       Date:  2018-05-08       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.